Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Some statements align with label sections provided (description/mechanism/route/AD indication and common adverse reactions), but there are multiple material inaccuracies or unsupported claims (notably: dosing regimen details, inclusion of generic/other-company manufacturing claims, and claims about generic-side-effect frequency/clinical events beyond label excerpts). Several label-critical items are not addressed or cannot be verified from the supplied label text.
Category Scores
Accurate Statements
Dupixent targets the IL-4 receptor alpha (IL-4Rα) subunit.
Section 12.1 Mechanism of Action: binds IL-4Rα.
IL-4 and IL-13 play a central role in Type 2 inflammation.
Mechanism/IL-4/IL-13 signaling described in Section 12.1 (support is indirect; this specific “Type 2 inflammation” phrasing is not explicitly provided in the excerpts).
Dupilumab inhibits IL-4 and IL-13 signaling by specifically binding to IL-4Rα.
Section 12.1 Mechanism of Action.
Dupixent is administered as a subcutaneous injection.
Section 2 Dosage and Administration: subcutaneous injection.
Dupixent is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
Section 1 Indications and Usage (AD indication).
Dupixent is contraindicated in patients with known hypersensitivity to dupilumab or any excipients of DUPIXENT.
Section 4 Contraindications.
Hypersensitivity reactions, including anaphylaxis, have been reported.
Section 5.1 Hypersensitivity.
Common side effects include conjunctivitis.
Section 6 Adverse Reactions: conjunctivitis listed under clinical trials experience.
Common side effects include injection site reactions.
Section 6 Adverse Reactions: injection site reactions listed under clinical trials experience.
Common side effects include oral herpes.
Section 6 Adverse Reactions: oral herpes listed under clinical trials experience.
Dupixent should not be used to treat acute symptoms or acute exacerbations of asthma or COPD; do not use for acute bronchospasm or status asthmaticus.
Section 5.4 Acute Symptoms of Asthma or COPD.
Dupixent is a sterile, liquid solution.
Section 11 Description: solution for subcutaneous injection.
Unsupported Statements
The engineered CHO cells are cultured in bioreactors under controlled conditions to allow them to produce the antibody.
No relevant label excerpt provided describing CHO cell culture conditions/bioreactors.
After cell culture, dupilumab is harvested and purified through filtration and chromatography steps.
No relevant label excerpt provided describing purification steps.
Dupixent is used to treat moderate-to-severe atopic dermatitis in adult and pediatric patients 6 months of age and older whose disease is not adequately controlled with topical therapies or when those therapies are not advisable.
This matches Section 1 AD indication, but the statement as written omits 'topical prescription therapies' wording; considered partially supported rather than fully unsupported. (No standalone full support evaluation for wording.)
Dupixent is indicated for the treatment of adults and children 12 years of age and older with inadequately controlled moderate-to-severe asthma with an eosinophilic phenotype or oral corticosteroid-dependent asthma.
Label excerpt provided indicates AD maintenance add-on in asthma for adults and pediatric patients aged 6 years and older, not specifically 12 years for asthma. The age restriction is unsupported.
Dupixent is approved for adults with chronic rhinosinusitis with nasal polyposis (CRSwNP).
Provided label excerpt indicates add-on maintenance treatment in adults and pediatric patients aged 12 years and older with inadequately controlled CRSwNP, not 'adults only'.
Common side effects of Dupixent include increased eosinophil count.
In the supplied label excerpts, eosinophils are not listed as a common adverse reaction.
In asthma patients, paradoxical bronchospasm has been reported with Dupixent.
The label excerpt provided states Dupixent should not be used for acute bronchospasm/status asthmaticus (Section 5.4), but does not report paradoxical bronchospasm as an adverse reaction.
The typical starting dose for atopic dermatitis in adults and children 12 years and older is 600 mg initially (two 300 mg injections).
No dosing regimen details for AD are included in the supplied label excerpts; cannot verify against Section 2 from provided text.
For atopic dermatitis in adults and children 12 years and older, the dose is 300 mg every two weeks thereafter.
No dosing regimen details for AD are included in the supplied label excerpts; cannot verify against Section 2 from provided text.
Dupixent is manufactured by Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.
No manufacturing/company attribution statements provided in the excerpts.
Information regarding patent exclusivity for Dupixent and its potential for generic competition can be found on DrugPatentWatch.com.
Not a prescribing information claim; no label support provided.
Many patients experience improvement in their symptoms within two to four weeks of starting Dupixent treatment.
No label excerpt provided with timeline of symptom improvement.
The full therapeutic effect of Dupixent may take longer to achieve.
No label excerpt provided with statements about onset/timing of full effect.
Dupixent's mechanism of action targeting IL-4Rα distinguishes it from other biologics that may target different cytokines or receptors involved in Type 2 inflammation.
Comparative/marketing-style framing not supported by supplied label excerpts.
The efficacy and side effect profiles can vary between different classes of biologic therapies.
Comparative/unsourced generalization not supported by supplied label excerpts.
Contradictions
Low
AI Statement
Dupixent is indicated for the treatment of adults and children 12 years of age and older with inadequately controlled moderate-to-severe asthma with an eosinophilic phenotype or oral corticosteroid-dependent asthma.
Label Reference
Section 1 Indications and Usage (asthma add-on maintenance: adults and pediatric patients aged 6 years and older).
Low
AI Statement
Dupixent is approved for adults with chronic rhinosinusitis with nasal polyposis (CRSwNP).
Label Reference
Section 1 Indications and Usage (CRSwNP add-on maintenance: adults and pediatric patients aged 12 years and older).
Important Omissions
Warnings include avoidance of live vaccines during treatment with DUPIXENT (Section 5.10).
Importance:
Moderate
Corticosteroid reduction guidance: do not discontinue systemic/topical/inhaled corticosteroids abruptly upon initiation (Section 5.5).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Material age/indication scope errors for asthma and CRSwNP could affect appropriateness. Several adverse-event claims (e.g., paradoxical bronchospasm; increased eosinophil count as common) and dosing regimen assertions are not supported by the provided label excerpts, increasing risk of misinformation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several claims are not verifiable or conflict with provided label excerpts (notably asthma and CRSwNP age indications) and key label-supported warnings (live vaccines; corticosteroid tapering) are omitted.
Suggested Improvement
Restrict indication statements to the label-provided age ranges; remove or rephrase unsupported adverse-event and dosing-regimen claims unless directly supported by the label text; include key warnings such as avoiding live vaccines and not abruptly discontinuing corticosteroids.